Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval? |
Does NVO Face Rising Competitive Pressure on LLY's Foundayo Approval?
Novo Nordisk faces rising pressure as LLY launches Foundayo, a rival obesity pill, challenging Wegovy despite data suggesting NVO's edge in efficacy.
Danish drugmaker Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its blockbuster semaglutide-based (GLP-1) drugs — Ozempic (for type II diabetes [T2D]) and Wegovy (for obesity). In late 2025, NVO expanded its obesity portfolio, securing FDA approval for oral Wegovy, the first GLP-1 therapy in pill form for weight management, in the United States, which was launched in early 2026.
This initially gave the company a huge head start over its nemesis in the obesity space, Eli Lilly $LLY LLY, which markets its tirzepatide (GLP-1) injections as Mounjaro for T2D and Zepbound for obesity. Eli Lilly’s Mounjaro and Zepbound directly rival Novo Nordisk’s Ozempic and Wegovy, and have recently gained significant market share, driven by stronger efficacy and superior commercial execution, fueling rising demand.
Earlier this month, Eli Lilly received FDA approval for its oral GLP-1 therapy, orforglipron, and subsequently launched it under the brand name Foundayo for adults with obesity or overweight with weight-related medical problems. A key differentiating factor is that the pill can be taken at any time of the day without food or water restrictions. When combined with a reduced-calorie diet and increased physical activity, Foundayo is designed to help individuals lose excess weight and maintain long-term weight management.
This makes Foundayo a........